Considering that an effective method to prevent DCM progression and HF is not recognized yet, CXCL10 ideally would represent an optimal biomolecular target to control early events in heart disease, either primary or secondary to T2D. Here, CXCL10 is linked to familial dilated cardiomyopathy.